Success Metrics

Clinical Success Rate
24.0%

Based on 12 completed trials

Completion Rate
24%(12/50)
Active Trials
0(0%)
Results Posted
233%(28 trials)
Terminated
38(72%)

Phase Distribution

Ph phase_2
53
100%

Phase Distribution

0

Early Stage

53

Mid Stage

0

Late Stage

Phase Distribution53 total trials
Phase 2Efficacy & side effects
53(100.0%)

Highest Phase Reached

Phase 2

Trial Status & Enrollment

Completion Rate

23.1%

12 of 52 finished

Non-Completion Rate

76.9%

40 ended early

Currently Active

0

trials recruiting

Total Trials

53

all time

Status Distribution
Completed(12)
Terminated(40)
Other(1)

Detailed Status

Terminated38
Completed12
Withdrawn2
Suspended1

Development Timeline

Analytics

Development Status

Total Trials
53
Active
0
Success Rate
24.0%
Most Advanced
Phase 2

Trials by Phase

Phase 253 (100.0%)

Trials by Status

suspended12%
terminated3872%
completed1223%
withdrawn24%

Recent Activity

0 active trials
Showing 5 of 53
suspendedphase_2

A Study of Atengenal and Astugenal in Diffuse, Intrinsic Pontine Glioma (DIPG)

NCT02742883
completedphase_2

Antineoplaston Therapy in Treating Children With Low-Grade Astrocytoma

NCT00003468
completedphase_2

Antineoplaston Therapy in Treating Children With Brain Tumors

NCT00003458
terminatedphase_2

Antineoplaston Therapy in Treating Patients With Ependymoma

NCT00003479
terminatedphase_2

Antineoplaston Therapy in Treating Patients With Multiple Myeloma

NCT00003511
View all 53 trials

Clinical Trials (53)

Showing 20 of 53 trialsScroll for more
NCT02742883Phase 2

A Study of Atengenal and Astugenal in Diffuse, Intrinsic Pontine Glioma (DIPG)

Suspended
NCT00003468Phase 2

Antineoplaston Therapy in Treating Children With Low-Grade Astrocytoma

Completed
NCT00003458Phase 2

Antineoplaston Therapy in Treating Children With Brain Tumors

Completed
NCT00003479Phase 2

Antineoplaston Therapy in Treating Patients With Ependymoma

Terminated
NCT00003511Phase 2

Antineoplaston Therapy in Treating Patients With Multiple Myeloma

Terminated
NCT00003487Phase 2

Antineoplaston Therapy in Treating Patients With Cancer of the Esophagus

Terminated
NCT00003508Phase 2

Antineoplaston Therapy in Treating Patients With Advanced Mesothelioma

Terminated
NCT00003498Phase 2

Antineoplaston Therapy in Treating Patients With Non-Hodgkin's Lymphoma

Terminated
NCT00003531Phase 2

Antineoplaston Therapy in Treating Patients With Stage IV Pancreatic Cancer

Terminated
NCT00003509Phase 2

Antineoplaston Therapy in Treating Patients With Stage IV Melanoma

Terminated
NCT00003526Phase 2

Antineoplaston Therapy in Treating Patients With Cancer of Unknown Primary Origin

Terminated
NCT00003492Phase 2

Antineoplaston Therapy in Treating Patients With Stage IV Lung Cancer

Terminated
NCT00003499Phase 2

Antineoplaston Therapy in Treating Patients With Low-Grade Non-Hodgkin's Lymphoma

Completed
NCT00003453Phase 2

Antineoplaston Therapy in Treating Patients With Stage IV Adrenal Gland Cancer

Terminated
NCT00003471Phase 2

Antineoplaston Therapy in Treating Patients With Low-Grade Astrocytoma

Terminated
NCT00003474Phase 2

Antineoplaston Therapy in Treating Adults With Residual/Recurrent/Progressive Glioblastoma Multiforme

Completed
NCT00003456Phase 2

Antineoplaston Therapy in Treating Patients With Newly-diagnosed Glioblastoma Multiforme

Completed
NCT00003472Phase 2

Antineoplaston Therapy in Treating Patients With Recurrent or Refractory Oligodendroglioma

Terminated
NCT00003535Phase 2

Antineoplaston Therapy in Treating Children With Recurrent or Refractory High-Grade Glioma

Terminated
NCT00003459Phase 2

Antineoplaston Therapy in Treating Patients With Brain Stem Glioma

Completed

Drug Details

Intervention Type
DRUG
Total Trials
53